Bezafibrate

ApprovedSmall molecule

IIntercept Pharmaceuticals

Bezafibrate is one of 190 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

189

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

MyopathyActive, not recruiting

Primary Biliary CirrhosisActive, not recruiting

Primary Biliary CholangitisActive, not recruiting

X-Linked AdrenoleukodystrophyActive, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

Acute Myocardial InfarctionApproved

Active, not recruiting

MyopathyPhase 2

Active, not recruiting

Primary Biliary CirrhosisPhase 3

Active, not recruiting

Primary Biliary CholangitisPhase 3

Active, not recruiting

X-Linked AdrenoleukodystrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Bezafibrate

IIntercept Pharmaceuticals

Approved

1 2

Inpefa

LLexicon Pharmaceuticals

Phase 3

1 3

Injectafer

AAmerican Regent, Inc.

Phase 3

1 4

Rimonabant

Sanofi

Phase 3

1 5

Genotropin

Repatha

5 7

Sibutramine Hydrochloride

AAbbott

Phase 3

1 8

Benicar

Novartis

Preclinical

1 9

Mounjaro

Eli Lilly

Preclinical

1 10

Praluent

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Recruiting

Cardiovascular Disease

NCT06858332

Clinical

Trials by Indication[1]

Primary Biliary Cirrhosis2 trials

Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders

Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 3·NCT02937012·34 enrolled

Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01654731·100 enrolled

Efficacy2 trials

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Terminated·IIntercept Pharmaceuticals·Phase 2·NCT04594694·75 enrolled

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Completed·IIntercept Pharmaceuticals·Phase 2·NCT05239468·72 enrolled

Metabolism1 trial

Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects

Completed·RRigshospitalet, Denmark·Phase 2·NCT00983788·12 enrolled

AFib1 trial

The Effect of Bezafibrate on Cholestatic Itch

Unknown status·—·Phase 3·NCT02701166·84 enrolled

Myopathy1 trial

A Study of Bezafibrate in Mitochondrial Myopathy

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT02398201·6 enrolled

9 more indications

Cardiovascular Disease1 trial

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Recruiting· Novartis logo

Novartis··NCT06858332·2,382 enrolled

Acute Coronary Syndrome1 trial

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Completed· Sanofi logo

Sanofi·Phase 4·NCT02984982·206 enrolled

Mixed Dyslipidemia1 trial

Bezafibrate Plus Berberine in Mixed Dyslipidemia

Completed·UUniversity of Guadalajara·Phase 3·NCT02548832·36 enrolled

X-linked adrenoleukodystrophy1 trial

The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)

Completed·—·N/A·NCT01165060·10 enrolled

Bipolar Depression1 trial

BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study

Recruiting·MMassachusetts General Hospital·Phase 2·NCT02481245·30 enrolled

Acute Myocardial Infarction1 trial

Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction

Completed·IInstituto Mexicano del Seguro Social·Phase 4·NCT02291796·100 enrolled

Trial1 trial

Bezafibrate Trial in CPT2 Deficiency

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00336167·12 enrolled

Primary Biliary Cholangitis1 trial

A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis

Unknown status·IInstituto Mexicano del Seguro Social·Phase 3·NCT04751188·11 enrolled

Unspecified1 trial

PC-300 Tea Effect on Triglyceride Levels

Completed·CCiprés Grupo Médico CGM SC·N/A·NCT03649269·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Bezafibrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bezafibrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bezafibrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Intercept Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IIntercept Pharmaceuticals

Bezafibrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Primary Biliary Cirrhosis2 trials

Efficacy2 trials

Metabolism1 trial

AFib1 trial

Myopathy1 trial

Cardiovascular Disease1 trial

Acute Coronary Syndrome1 trial

Mixed Dyslipidemia1 trial

X-linked adrenoleukodystrophy1 trial

Bipolar Depression1 trial

Acute Myocardial Infarction1 trial

Trial1 trial

Primary Biliary Cholangitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News